Virtual Grand Rounds: Medication Treatments for Anxiety Disorders

Presented by
Amir Garakani, M.D.
Psychiatrist and Director of Education
Silver Hill Hospital
Wednesday, May 12th, 2021
11:30 a.m. - 1:00 p.m.
Live Presentation via Zoom
Anxiety disorders, in particular panic, generalized anxiety and social anxiety disorders, along with specific phobias, are among the most common psychiatric disorders and are a leading cause of disability and work and school absences. Early treatment of anxiety included the use of benzodiazepines along with psychotherapy although the ascent of tricyclic antidepressants, followed by selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), became the accepted and recommended first-line medications for anxiety disorders. Although medication treatment, along with cognitive behavioral and exposure therapy, are often felt to be sufficient treatments for anxiety, a sizeable portion of patients continue to experience continued anxiety and poor treatment response or intolerance of SSRI or SNRI medications. This is further complicated by high rates of comorbidity of anxiety with depression and bipolar disorders and substance use disorders. While depression and schizophrenia have seen a rise in novel medication approaches, there has been a comparatively smaller amount of research focus on anxiety disorders. The purpose of this lecture is to briefly review the current medication treatments for anxiety disorders and then discuss the state of research on novel pharmacologic approaches to anxiety.
Accreditation Statement: Silver Hill Hospital is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.
Designation Statement: Silver Hill Hospital designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This program has been approved for 1.5 Continuing Education Credit Hours by the National Association of Social Workers, CT and meets the continuing education criteria for CT Social Work Licensure renewal. Approval also meets the continuing education criteria for CT LMFTs, LPCs, and licensed psychologists.

[@pavanpyda]

1:01:39 Ketamine is NMDA antagonist; 58:27 Vilazodone is 5HT1A partial agonist(not an antagonist)

[@norellern6155]

Can you please post the link for me to read????